Unibest 优贝德
← Back to patent-cliff list

西诺氨酯

Tier C — Watch / trade

Cenobamate

SK Biopharmaceuticals Co Ltd
Originator
2019
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type

TargetsSCNA、GABAAR

BrandXcopri、Ontozry、翼弗瑞

Indications (approved)癫痫部分性发作、癫痫、癫痫发作

Regional status

US
批准上市
2019-11-21
EU
批准上市
2021-03-26
China
批准上市
2025-12-03
Japan
临床三期
2021-03-08

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 1 · Total yield /
Synthetic routes & intermediates Route 1
CodeCAS No.Intermediate
CENO-00162566-66-9Available(R)-2-(2-chlorophenyl)oxirane
CENO-002288-94-8Available1H-tetrazole

Frequently asked questions

What are the approved indications of Cenobamate?

Approved indications include: 癫痫部分性发作, 癫痫, 癫痫发作.

When does the Cenobamate patent expire?

No public expiry year is available for Cenobamate yet; this page updates once verified.

How many synthesis routes are recorded for Cenobamate?

1 synthesis routes are recorded; the shortest is 1 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Cenobamate intermediates?

2 intermediate CAS of Cenobamate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Cenobamate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-24